Amicus Therapeutics, Inc.
FOLD
$14.38
$0.010.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 634.21M | 598.70M | 571.16M | 543.14M | 528.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 634.21M | 598.70M | 571.16M | 543.14M | 528.30M |
| Cost of Revenue | 72.93M | 61.22M | 55.03M | 51.07M | 52.94M |
| Gross Profit | 561.28M | 537.49M | 516.13M | 492.07M | 475.35M |
| SG&A Expenses | 383.49M | 353.07M | 338.14M | 327.18M | 323.38M |
| Depreciation & Amortization | 7.46M | 7.60M | 7.90M | 8.23M | 8.55M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 599.72M | 564.19M | 546.11M | 495.35M | 494.23M |
| Operating Income | 34.49M | 34.52M | 25.05M | 47.79M | 34.06M |
| Income Before Tax | 191.00K | 4.98M | -22.51M | -3.22M | -28.76M |
| Income Tax Expenses | 27.30M | 19.04M | 15.59M | 26.16M | 27.35M |
| Earnings from Continuing Operations | -27.11 | -14.06 | -38.10 | -29.37 | -56.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.11M | -14.06M | -38.10M | -29.37M | -56.11M |
| EBIT | 34.49M | 34.52M | 25.05M | 47.79M | 34.06M |
| EBITDA | 41.95M | 42.12M | 32.95M | 56.02M | 42.61M |
| EPS Basic | -0.09 | -0.05 | -0.12 | -0.10 | -0.19 |
| Normalized Basic EPS | 0.00 | 0.01 | -0.04 | 0.00 | -0.04 |
| EPS Diluted | -0.09 | -0.05 | -0.13 | -0.10 | -0.19 |
| Normalized Diluted EPS | 0.00 | 0.01 | -0.04 | 0.00 | -0.04 |
| Average Basic Shares Outstanding | 1.23B | 1.23B | 1.23B | 1.22B | 1.22B |
| Average Diluted Shares Outstanding | 1.24B | 1.23B | 1.23B | 1.22B | 1.22B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |